Kymera Therapeutics, Inc.·4

Aug 19, 4:30 PM ET

Chesworth Richard 4

4 · Kymera Therapeutics, Inc. · Filed Aug 19, 2021

Insider Transaction Report

Form 4
Period: 2021-08-17
Chesworth Richard
Chief Scientific Officer
Transactions
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2021-08-1754,000297,119 total
    Exercise: $20.00Exp: 2030-08-19Common Stock (54,000 underlying)
  • Sale

    Common Stock

    2021-08-17$49.90/sh8,809$439,61245,191 total
  • Sale

    Common Stock

    2021-08-17$51.68/sh2,928$151,325288 total
  • Exercise/Conversion

    Common Stock

    2021-08-17$20.00/sh+54,000$1,080,00054,000 total
  • Sale

    Common Stock

    2021-08-17$50.37/sh41,975$2,114,2433,216 total
  • Sale

    Common Stock

    2021-08-17$52.09/sh288$15,0020 total
Footnotes (6)
  • [F1]This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2020.
  • [F2]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $49.04 to $50.03. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
  • [F3]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $50.04 to $51.02. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
  • [F4]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $51.05 to $52.00. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
  • [F5]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $52.06 to $52.16. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
  • [F6]Twenty-five percent (25%) of the shares subject to this option vested and became exercisable on August 17, 2021, and the remainder of the shares shall vest in equal monthly installments for a period of thirty-six (36) months thereafter.

Documents

1 file
  • 4
    doc4.xmlPrimary

    FORM 4 SUBMISSION